| (84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
| (30) |
Priority: |
17.12.2012 US 201261738223 P
14.02.2013 EP 13000746
|
| (43) |
Date of publication of application: |
|
21.10.2015 Bulletin 2015/43 |
| (60) |
Divisional application: |
|
21199413.2 |
| (73) |
Proprietor: Cell Medica Inc. |
|
Houston, TX 77036 (US) |
|
| (72) |
Inventors: |
|
- HONEGGER, Annemarie
CH-8057 Zürich (CH)
- KRETZSCHMAR, Titus
6331 Hühnenberg (CH)
- SCHMITT, Simone
8953 Dietikon (CH)
- SHAMSHIEV, Abdijapar
CH-8053 Zürich (CH)
- GRABULOVSKI, Stefanie
CH-8049 Zürich (CH)
|
| (74) |
Representative: Grünecker Patent- und Rechtsanwälte
PartG mbB |
|
Leopoldstraße 4
80802 München
80802 München (DE) |
| (56) |
References cited: :
WO-A1-2011/140522
WO-A2-2004/067568
WO-A2-2007/002261
US-A1- 2003 026 806
|
WO-A1-2011/140522
WO-A2-2007/002261
US-A1- 2003 026 806
|
|
| |
|
|
- ALTEN RIEKE ET AL: "The human anti-IL-1Î monoclonal antibody ACZ885 is effective in
joint inflammation models in mice and in a proof-of-concept study in patients with
rheumatoid arthritis", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB,
vol. 10, no. 3, 5 June 2008 (2008-06-05), page R67, XP021041234, ISSN: 1478-6354
- Rieke Alten ET AL: "Efficacy and safety of the human anti-IL-1beta monoclonal antibody
canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding
study July 2011) Background", BMC Musculoskeletal Disorders, 1 January 2011 (2011-01-01),
page 153, XP055420326, Retrieved from the Internet: URL:https://www.ncbi.nlm.nih.gov/pmc/artic
les/PMC3152943/pdf/1471-2474-12-153.pdf [retrieved on 2017-10-31]
- Jianying Qi ET AL: "A bispecific antibody against IL-1&bgr; and IL-17A is beneficial
for experimental rheumatoid arthritis", International Immunopharmacology, vol. 14,
no. 4, 1 December 2012 (2012-12-01), pages 770-778, XP055140680, ISSN: 1567-5769,
DOI: 10.1016/j.intimp.2012.10.005
|
|
